

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

NCT07010159

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Kiniksa Pharmaceuticals International, plc
Enrollment	165 participants

Key Eligibility Criteria

Inclusion (5)

- Phase 2 and 3: Has a diagnosis of recurrent pericarditis
- Phase 2 and 3: Has signs and symptoms of recurrent pericarditis despite treatment with standard therapies
- Phase 2 and 3: Weighs at least 40 kg
- Phase 2: Taking NSAIDS and/or colchicine (in any combination)
- Phase 3: Taking NSAIDs and/or colchicine and/or glucocorticoids (in any combination)

Exclusion (11)

- Phase 2 and 3: Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies.
- Phase 2 and 3: Has received an investigational drug during the 4 weeks before screening or is planning to receive an investigational drug at any time during the study.
- Phase 2 and 3: Has a history of active or untreated, latent tuberculosis (TB) prior to screening.
- Phase 2 and 3: Has a history of immunodeficiency.
- Phase 2 and 3: Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.

... and 6 more (see full listing online)

Locations (46 total)

Investigational Site 018, Gilbert, Arizona, United States
Investigational Site 030, Los Angeles, California, United States
Investigational Site 008, San Francisco, California, United States
... and 43 more locations